Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study

• Published in: Arthritis research & therapy Vol. 22; no. 1; pp. 1 - 8
• Main Authors: Sharma, Shefali Khanna, Jain, Siddharth, Bahl, Pooja, Potturi, Pragna, Rathi, Manish, Naidu, Shankar, Sachdeva, Naresh, Dhir, Varun, Jain, Sanjay
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 14.08.2020; BioMed Central; BMC
• Subjects: Analysis; Arthritis; Biopsy; Cohort analysis; Cyclophosphamide; Drug dosages; Estradiol; Females; Gonadotoxicity; Hematology; Hormone replacement therapy; Inhibins; Lupus; Medical research; Menstruation; Mycophenolate mofetil; Ovarian dysfunction; Ovaries; Serology; Statistical analysis; Systemic lupus erythematosus; Thrombocytopenia; Women's health; Young adults; Youth; India

Background Ovarian toxicity is a dreaded complication of cyclophosphamide (CYC). With the use of lower cumulative doses of intravenous CYC (modified NIH regimens) and availability of better markers of ovarian toxicity, the incidence of ovarian dysfunction needs reassessment. Lupus disease activity,...